Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTDB5IS)

• DTT Name: Receptor unspecific (Rec)
• Gene Name: Rec
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T09937

Molecular Interaction Atlas (MIA) of This DTT

4 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATL-104	DMD0I29	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Prosaptide TX14(A)	DME25TI	Neuropathic pain	8E43.0	Phase 2	[3]
BT-063	DMS4H30	Autoimmune diabetes	5A10	Phase 1	[1]
Lactermin	DM8ANIM	Oral mucositis	DA01.11	Phase 1	[4]

2 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PV-707	DMRODZS	Skin burns	ME65.0	Discontinued in Phase 2	[5]
YP-004	DMK1UJM	Solid tumour/cancer	2A00-2F9Z	Terminated	[6]

References

• [1] Clinical pipeline report, company report or official report of Biotest.
• [2] Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9.
• [3] Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81.
• [4] Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75.
• [5] EP patent application no. 1904089, Promotion of epithelial regeneration.
• [6] CA patent application no. 815512, Method for increasing the efficiency of double-strand break-induced mutagenesis.